Drug intelligence / Profile preview

C1

Development stage: Unknown
Lead developer: Takeda

Overview

The identifier 'C1' is used non-specifically across various contexts in the provided clinical trial information. It refers to at least two distinct vaccine candidates: nOPV2 vaccine candidate C1 for poliomyelitis and VB10.2129 (C1) for COVID-19. Additionally, 'C1' is used to denote dental implants (MIS C1 Implants), study phases, cervical vertebrae, study cohorts, stimulation settings, and a weight control video intervention. It is also part of the name for a platinum-containing anticancer agent (BP-C1) and the C1 esterase inhibitor protein (C1INH/rhC1-INH).

Beyond the preview

Go deeper on C1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C1.

Explore the full profile